By The Yoshinori Yoshida laboratory reports the generation of a platform of human heart organoids derived from iPS cells, which they use to test new therapeutic alternatives on cardiac fibrosis. Their study is published in Frontiers in Cell and Developmental Biology.
Immunosuppressive regimens after a heart transplant can hamper good therapeutic progressions in fibrosis
Focused chemists in lab coats and safety goggles making experiments.
Comments